Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
about
NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell EngraftmentThe complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activityIdentification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects.Acute graft-versus-host disease: a bench-to-bedside update.Functional Reconstitution of Natural Killer Cells in Allogeneic Hematopoietic Stem Cell TransplantationNatural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation.The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD.A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against RhabdomyosarcomaNK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation.Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation.Advances in graft-versus-host disease biology and therapy.Nutrient support in hematopoietic cell transplantation.Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells.Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantationHDAC inhibition and graft versus host diseaseAcute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.Blockade of Vascular Endothelial Growth Factor (VEGF) Aggravates the Severity of Acute Graft-versus-host Disease (GVHD) after Experimental Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors.Adoptive Transfer of Treg Cells Combined with Mesenchymal Stem Cells Facilitates Repopulation of Endogenous Treg Cells in a Murine Acute GVHD Model.Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicityRapid generation of a functional NK-cell compartment.Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.Natural killer cells: can they be useful as adoptive immunotherapy for cancer?Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors-A Retrospective Study.Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors.Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effectsIL-12/15/18-preactivated NK cells suppress GvHD in a mouse model of mismatched hematopoietic cell transplantationIn vivo imaging using bioluminescence: a tool for probing graft-versus-host disease.Immunological aspects of Candida and Aspergillus systemic fungal infections.NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell PhenotypeLymphoid reconstruction and vaccines.Plasmacytoid precursor dendritic cells from NOD mice exhibit impaired function: are they a component of diabetes pathogenesis?In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activityTargeting deacetylases to improve outcomes after allogeneic bone marrow transplantation.Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation.Biology of chronic graft-versus-host disease: implications for a future therapeutic approach.Killer Immunoglobulin-like Receptors (KIR) haplogroups A and B track with Natural Killer Cells and Cytokine Profile in Aged Subjects: Observations from Octo/Nonagenarians in the Belfast Elderly Longitudinal Free-living Aging STudy (BELFAST).
P2860
Q26765845-31881332-811C-438A-8317-5F46ECE1FB3FQ26851545-1A0CF548-70B9-4F01-AB47-863B1714CAAEQ27301956-6701DFCF-7B64-4057-BDC2-BDF669851271Q27687130-CEC3982C-7A5B-4F56-B272-4D976E8C9FB8Q28069682-3C901FF2-F5E5-4815-AC47-D8F219C17CB7Q33600093-45DA87C3-B127-47F2-A158-2EC2D22AE6A8Q33643965-18F6D7CC-E805-4BE6-84AF-252AEFDB7931Q33785788-09FEB8FA-E816-4E3B-98F1-FF4A19B8197DQ33887452-8E3AA197-674A-4D7A-BEEB-45336DF36149Q33893091-DECAD769-E17D-493A-AA70-1822531258E7Q33895386-EB234FAF-4EE5-4427-AB91-31B63CA8DDF1Q34031916-14FAF169-3B30-4D61-9958-AD82922151C9Q34297653-C63E7DFA-EA8D-4EC4-984D-48E854D5B5DCQ34600272-5AEF3A6A-91C9-4B89-8F48-652FDB576B89Q34649004-218CC0AE-7DF1-4D17-B235-51BA4F72D1A4Q35016985-0E0F6EA3-508E-438C-9D57-EACCE344BCE1Q35029441-16105A85-E1B2-4736-AA71-EA4D1463FB95Q35745507-E5350E17-E488-4389-A7BF-F8D7637BAB59Q35751074-136B6F47-BE0D-4FDC-A49D-B27DD61A8090Q35783066-7557A332-9891-4636-9783-DC25635B0B6DQ35847425-34BC3537-B3E6-47D7-8DEE-2E5043EB775EQ35848453-9D4F24F6-D007-4DF1-91D0-ED9AF98320ECQ35990718-57CB0366-1D80-4769-BF89-B74B478AC978Q36061068-E9CFD2B6-D74E-485E-A4E9-564DCD7A1BD8Q36065944-BB7350F2-9F89-4E90-9820-0C2E2674E5C6Q36251308-E33B7210-D998-4DD6-8874-ED384A02F0C6Q36255385-86B1B2AA-DDA9-441C-B996-B941F3272AE0Q36304574-3EEEE11F-0EAD-4A40-A5D3-FDA43298F093Q36380188-E731DCD0-B78B-45A3-9266-844372D35248Q36393953-B09EA6D6-8EB1-40C6-8109-11BD4656DF5EQ36488762-14103E82-4FE5-4A49-B8F9-043FA9C5C7FBQ36587261-02A9EDF8-DCDD-4966-A746-AF728CF23DD2Q36660550-8A869C10-078F-49CB-B1A0-9FF9177B4C27Q36707846-8BF0D25D-1588-4120-BCAD-0B691D94BD39Q36842578-5E3A5F60-1EC7-457E-8A6D-669DA9937A12Q36868792-63DBBC83-C7C7-4C37-BE3D-67C89026C0CDQ37026059-3BAEB366-2A7B-4D67-959F-FAFD152F1AF4Q37162888-57B3B2C8-2B06-4A3A-9309-F919B45FC6DAQ37294468-3FD69A4B-5BA7-4AF7-B7E9-B61CD8A1CD0CQ37308200-F749F8E0-88C7-4641-B5EA-76415CB1A560
P2860
Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 1998
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Suppression of graft-versus-ho ...... c bone marrow transplantation.
@en
Suppression of graft-versus-ho ...... c bone marrow transplantation.
@nl
type
label
Suppression of graft-versus-ho ...... c bone marrow transplantation.
@en
Suppression of graft-versus-ho ...... c bone marrow transplantation.
@nl
prefLabel
Suppression of graft-versus-ho ...... c bone marrow transplantation.
@en
Suppression of graft-versus-ho ...... c bone marrow transplantation.
@nl
P2093
P2860
P356
P1476
Suppression of graft-versus-ho ...... c bone marrow transplantation.
@en
P2093
Hornung RL
Ruscetti FW
P2860
P304
P356
10.1172/JCI1268
P407
P577
1998-05-01T00:00:00Z